Wall Street analyst estimates for Kazia Therapeutics Ltd ADR (KZIA): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous...
Analyst Consensus
| Strong Buy | 0 |
| Buy | 3 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 3 |
| Avg rating (1-5) | 1.00 |
Valuation Ratios
| Price / Book | 0.95 |
| EV / EBITDA | 2.30 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.1M | $8.8M | $13108 | $1565 | $988110 | $15.2M | $10000 | $555 | $2.3M | $42000 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | $4.1M | $8.8M | $13108 | $1565 | $988110 | $15.2M | $10000 | $555 | $2.3M | $42000 |
| Research & Development | $9.9M | $11.1M | $9.8M | $6.5M | $9.5M | $14.5M | $20.2M | $15.6M | $17.4M | $7.3M |
| Selling, General & Admin | $5.8M | $8.5M | $5.6M | $3.8M | $3.7M | $7.0M | $5.2M | $8.6M | $13.6M | $8.7M |
| Operating Expenses | $15.6M | $19.7M | $14.7M | $10.3M | $13.2M | $21.6M | $25.4M | $24.1M | $30.8M | $14.3M |
| Operating Income | -$12.8M | -$10.9M | -$12.5M | -$8.4M | -$12.2M | -$6.4M | -$25.4M | -$24.1M | -$28.5M | -$14.2M |
| EBITDA | -$11.7M | -$9.4M | -$10.8M | -$7.7M | -$11.1M | -$5.1M | -$23.5M | -$22.3M | -$26.6M | -$13.3M |
| Interest Expense | 0 | 0 | 0 | $2.2M | 0 | 0 | $2094 | 0 | 0 | 0 |
| Pre-tax Income | -$12.2M | -$10.9M | -$6.3M | -$10.6M | -$12.8M | -$8.9M | -$25.4M | -$20.7M | -$27.0M | -$22.4M |
| Income Tax | $2.8M | -$198544 | -$305000 | -$298000 | -$298195 | -$484000 | -$368000 | -$271092 | -$271000 | -$1.7M |
| Net Income | -$12.1M | -$10.7M | -$6.0M | -$10.3M | -$12.5M | -$8.4M | -$25.0M | -$20.5M | -$26.8M | -$20.7M |
| EPS | $-135.20 | $-109.30 | $-59.80 | $-85.60 | $-80.00 | $-35.80 | $-95.00 | $-55.00 | $-55.00 | $-18.90 |
| EPS (Diluted) | $-135.20 | $-109.30 | $-59.80 | $-85.60 | $-80.00 | $-35.80 | $-95.00 | $-55.00 | $-55.00 | $-18.90 |
| Shares Outstanding (Diluted) | $89203 | $97634 | $100959 | $120007 | $152459 | $235400 | $265000 | $368600 | $479600 | $1.1M |
Price
| Price | $10.20 |
| Market Cap | $17M |
| Exchange | NASDAQ |
| Country | AU |
Related companies: BDRX · CANF · CMND · CNSP · GRI · INM · OGEN
Explore sector: Healthcare · Biotechnology
More sections of KZIA: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks